These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 29149337

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M, López-Calleja AI, Mulet X, Fraile-Ribot PA, Cabot G, Huarte R, Rezusta A, Oliver A.
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [Abstract] [Full Text] [Related]

  • 3. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
    Arca-Suárez J, Lasarte-Monterrubio C, Rodiño-Janeiro BK, Cabot G, Vázquez-Ucha JC, Rodríguez-Iglesias M, Galán-Sánchez F, Beceiro A, González-Bello C, Oliver A, Bou G.
    J Antimicrob Chemother; 2021 Jan 01; 76(1):91-100. PubMed ID: 33083833
    [Abstract] [Full Text] [Related]

  • 4. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G.
    Antimicrob Agents Chemother; 2022 Feb 15; 66(2):e0206721. PubMed ID: 34930034
    [Abstract] [Full Text] [Related]

  • 5. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.
    Antimicrob Agents Chemother; 2017 Nov 15; 61(11):. PubMed ID: 28874376
    [Abstract] [Full Text] [Related]

  • 6. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.
    Int J Antimicrob Agents; 2019 Jun 15; 53(6):774-780. PubMed ID: 30831233
    [Abstract] [Full Text] [Related]

  • 7. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
    Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A.
    Antimicrob Agents Chemother; 2019 Oct 15; 63(10):. PubMed ID: 31383659
    [Abstract] [Full Text] [Related]

  • 8. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
    Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A.
    Antimicrob Agents Chemother; 2014 Jun 15; 58(6):3091-9. PubMed ID: 24637685
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C, Schultze T, Göttig S, Kessel J, Schröder A, Tietgen M, Besier S, Burbach T, Häussler S, Wichelhaus TA, Hack D, Kempf VAJ, Hogardt M.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0169722. PubMed ID: 36190424
    [Abstract] [Full Text] [Related]

  • 16. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    J Antimicrob Chemother; 2022 Dec 23; 78(1):252-256. PubMed ID: 36411249
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
    Gomis-Font MA, Cabot G, López-Argüello S, Zamorano L, Juan C, Moyá B, Oliver A.
    J Antimicrob Chemother; 2022 Mar 31; 77(4):957-968. PubMed ID: 35084040
    [Abstract] [Full Text] [Related]

  • 20. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T, Arena F, Pollini S, Di Pilato V, D'Andrea MM, Henrici De Angelis L, Bassetti M, Rossolini GM, Pseudomonas aeruginosa Working Group.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):664-671. PubMed ID: 29216350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.